Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohi…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Suspended

Recruitment status

not reported

Planned enrollment

Timing not reported

Primary-completion proxy

Executive view

ACTRN12623001126606 evaluates Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University) in Glioblastoma Multiforme. The disclosed sponsor is QIMR Berghofer Medical Research Institute, the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is not reported, assessed over an unreported time frame.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ACTRN12623001126606 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Glioblastoma Multiforme landscape. Drug & Asset MCP drug_fetch was queried for Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University), while Company & Deal Intelligence MCP organization_fetch was queried for QIMR Berghofer Medical Research Institute.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
ACTRN12623001126606	Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University)	Phase 1/2 / Suspended	QIMR Berghofer Medical Research Institute	Australia		Timing not reported
NCT06703255	Temozolomide	Phase 1/2 / Recruiting	Hangzhou Hansi Biological Pharmaceutical Co., Ltd.	China	Part I: Number of participants experiencing Adverse Events (AEs) All AEs up to 28(±7)days after the last dose of study treatment	2026-12-31
NCT06691308	WL-276 (Imunopharm)	Early Phase 1 / Not yet recruiting	Beijing Imunopharm Technology Co., Ltd.	Geography not reported	Evaluate the safety（Adverse event incidence rate、Incidence rate of abnormal laboratory test results） and tolerability（D… Within 28 days after infusion	2027-05-31
NCT06687681	Allogenic NK cell(Kian Immune Cell Company)	Phase 2 / Recruiting	Kian immune Cell Company	Iran	To measure tumor response after infusion of intrathecal NK cells From enrollment to the end of treatment at 12 months	2025-11-25
NCT06672575	Ivonescimab	Phase 1/2 / Recruiting	The University of Texas MD Anderson Cancer Center	United States	Safety and Adverse Events (AEs) Through study completion; an average of 1 year	2028-01-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

ACTRN12623001126606 is a Phase 1/2, suspended study with not reported planned participants. Allocation is Non-randomised trial, masking is Open (masking not used), and the intervention model is not reported.

The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: The safety of the intervention, evaluated with the properties, incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs), abnormal laboratory parameters, vital signs including temperature (thermometer), heart rate (pulse oximeter), respiratory rate (counting breaths per minute), blood pressure (blood pressure monitor) and oxygen saturation (pulse oximeter), and electrocardiogram results. This outcome is a primary outcome in Phase I and a secondary outcome in Phase II.[ Adverse events will be collected at Days 0, 3, 7, 14, 21, 28, 31, 35, 49 and 70, then every 42 days thereafter dur….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Glioblastoma Multiforme. These records do not establish direct evidence for ACTRN12623001126606 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University) is indexed as T-lymphocyte cell therapy with target not reported biology and a global stage of Phase 1. The asset profile lists The Ohio State University as an originator or developer.

QIMR Berghofer Medical Research Institute is indexed in an unreported country with the website https://www.qimrberghofer.edu.au. Queensland Institute of Medical Research focuses on cancer, infectious diseases, mental health, and a range of chronic disorders. The record lists 4 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: ACTRN12623001126606
Protocol source: https://anzctr.org.au/ACTRN12623001126606.aspx
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes(The Ohio State University) in Glioblastoma Multiforme is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP